Bone and Joint Infection Clinical Trial
Official title:
Daptomycin > 6 mg/kg/Day as Salvage Therapy in Patients With Complex Bone and Joint Infection: Cohort Study in a Regionalreference Center
The choice of antimicrobial therapy to treat complex bone and joint infections (BJI) is
challenging, requiring consideration of: (i) the problem of bone diffusion; (ii) the
necessity of using antimicrobials active against bacterial biofilms; (iii) the growing
incidence of antibiotic resistance; and (iv) the high risk of severe adverse events (SAE) in
response to first-line antimicrobials in these patients.
Consequently, off-label use of recently developed antimicrobials, such as daptomycin, is
frequently required as salvage therapy in complex BJI. Even if daptomycin does not have
approval for the treatment of BJI, the Infectious Diseases Society of America guidelines
propose this antibiotic as alternative therapy for prosthetic joint infection. The
recommended dose is 6 mg/kg/d, whereas recent data support the use of higher doses in these
patients as bone penetration of daptomycin is limited.
The present cohort study aimed to assess the safety and efficacy of prolonged high-dose (>6
mg/kg/d) daptomycin salvage therapy in patients with complex BJI.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Not yet recruiting |
NCT05421312 -
Periarticular Penetration of Cefazolin and Clindamycin in Second Stage Revision Arthroplasty of the Hip
|
Phase 4 | |
| Active, not recruiting |
NCT04563325 -
Oral-only Antibiotics for Bone and Joint Infections in Children
|
Phase 4 | |
| Completed |
NCT03627000 -
Microbiological Epidemiology in Patients Experiencing Microbiological or Clinical Failure Following Reimplantation After a 2-stage Exchange Strategy for Hip or Knee Prosthetic Joint Infection
|
||
| Completed |
NCT03311113 -
Adherence to Oral Antibiotics In Patients With Osteoarticular Infections
|
||
| Recruiting |
NCT05753215 -
Controlled Trial of Omadacycline Randomized Treatment Given for Bone and Joint Infection
|
Phase 2 | |
| Completed |
NCT03209921 -
Pharmacokinetic Variability of Daptomycin During Prolonged Therapy for Bone and Joint Infections
|
N/A | |
| Completed |
NCT04418882 -
Septic Management and Outcome of Open Fracture
|
||
| Completed |
NCT05248490 -
Impact of Pharmaceutical Interviews Regarding the Management of Adverse Effects Related to the Antibiotic Therapy Used to Treat Osteoarticular Infections During Return Home
|
N/A | |
| Completed |
NCT03624855 -
Implant-Associated P. Aeruginosa Bone And Joint Infections : Experience In A Regional Reference Center In France
|
||
| Recruiting |
NCT04496024 -
Ofloxacin Concentration-toxicity Relationship in the Elderly
|
N/A | |
| Recruiting |
NCT04933344 -
Pharmacokinetics and Toxicodynamics of Daptomycin in Bone and Joint Infections
|
||
| Recruiting |
NCT04538053 -
BonE and Joint Infections - Simplifying Treatment in Children Trial
|
Phase 4 | |
| Completed |
NCT04373278 -
Infection After Free Fibula Flap Reconstruction of the Mandible: a Retrospective Cohort Study
|
||
| Recruiting |
NCT02817711 -
Lyon BJI Cohort Study
|
N/A | |
| Recruiting |
NCT03611634 -
Consitution Of A Biological Collection From Samples From The Gut Microbiote In Patients Having A Bone Or Joint Infection Treated By A Suppressive Subcutaneous Antibiotherapy With Betalactamine
|
||
| Completed |
NCT03177369 -
Teicoplanin-based Antimicrobial Therapy in Staphylococcus Aureus Bone and Joint Infection: Tolerance, Efficacy and Experience With Subcutaneous Administration
|
N/A | |
| Recruiting |
NCT04722926 -
Lyon PJI Retrospective Cohort Study
|
||
| Completed |
NCT03852784 -
Osteoarticular Infections With Pneumococcal
|
||
| Recruiting |
NCT03796104 -
Prognostic Impact of Delta-haemolysin Production Deficiency in Staphylococcus Aureus on the Prognosis of Infected Implant Treated by DAIR
|
||
| Completed |
NCT03848104 -
Evaluation of the Use of Cefoxitin in Combination in Continuous Parenteral Administration in the Treatment of Bone and Joint Infections
|